MYD88 and diffuse large B-cell lymphoma: This pooling analysis showed that DLBCL patients with the MYD88 L265P mutation had low overall survival rates (HR = 3.244; 95% CI: 1.784–5.826; p < 0.001, Q = 0.068, I2 = 0.000) (Supplementary Fig. S1).